Evaluation of therapeutic efficacy of capecitabine on human breast carcinoma tissues and cell lines in vitro

Biomedicine and Pharmacotherapy

Volumn 61, Issue 9 SPEC. ISS., 2007, Pages 553-557

  Loo, Wings T Y ^a,b   Sasano, Hironobu ^a   Chow, Louis W C ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIMED Medical Institute   (Hong Kong)

Author keywords

Apoptosis; Capecitabine; Cytotoxic drugs; Monotherapy; Prodrug

Indexed keywords

ADENOSINE TRIPHOSPHATE; CAPECITABINE; DOCETAXEL; EPIRUBICIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOASSAY; BIOLUMINESCENCE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER PATIENT; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; METABOLIC RATE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID TUMOR;

EID: 35348923109     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.08.014     Document Type: Article

References (19)

1. Miwa M., Ura M., Nishida M., Sawada N., Ishikawa T., Mori K., et al. Design of a novel oral fluoropyrimidine carbamate, Capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34 (1998) 1274-1281
2. Blum J.L., Jones S.E., Buzdar A.U., LoRusso P.M., Kuter I., Vogel C., et al. Multicenter phase II study of Capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17 (1999) 485-493
3. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 18 (2000) 343-354
4. Verma S., Maraninchi D., O'Shaughnessy J., Jamieson C., Jones S., Martin M., et al. Capecitabine plus docetaxel combination therapy. Cancer 103 (2005) 2455-2465
5. Fumoleau P., Seidman A.D., Trudeau M.E., Chevallier B., and Ten Bokkel Huinink W.W. Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investig Drugs 6 (1997) 1853-1865
6. Lyseng-Williamson K.A., and Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 65 (2005) 2513-2531
7. Lasfargues E.Y., Coutinho W.G., and Redfield E.S. Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 61 (1978) 967-978
8. Spillman M.A., and Bowcock A.M. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 13 (1996) 1639-1645
9. Bardon S., Vignon F., Montcourrier P., and Rochefort H. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47 (1987) 1441-1448
10. Bennett J.A., Zhu S., Pagano-Mirarchi A., Kellom T.A., and Jacobson H.I. Alpha-fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts. Clin Cancer Res 4 (1998) 2877-2884
11. Tse E.Y.T., Loo W.T.Y., Cheung M.N.B., Chow L.W.C., and Cheng C.W. Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence. Life Sci 76 (2004) 827-834
12. Loo W.T., Cheung M.N., and Chow L.W. The inhibitory effect of a herbal formula comprising ginseng and carthamus tinctorius on breast cancer. Life Sci 76 (2004) 191-200
13. Eastman A., and Rigas J.R. Modulation of apoptosis signaling pathways and cell cycle regulation. Semin Oncol 26 (1999) 7-16
14. Cree I.A., Pazzagli M., Mini E., Mazzei T., Hunter E.M., Sutherland L.A., et al. Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay. Anticancer Drugs 6 (1995) 398-404
15. Hunter E.M., Sutherland L.A., Cree I.A., Dewar J.A., Preece P.E., Wood R.A., et al. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 19 (1993) 242-249
16. Kurbacher C.M., Mallmann P., Kurbacher J.A., Hubner H., and Krebs D. Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay. Geburtshilfe Frauenheilkd 56 (1996) 70-78
17. Urruticoechea A., Smith I.E., and Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23 (2005) 7212-7220
18. Scholzen T., and Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 182 (2000) 311-322
19. Ciccolini J., Fina F., Bezulier K., Giacometti S., Roussel M., Evrard A., et al. Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas. Mol Cancer Ther 1 (2002) 923-927